Ten stocks capped off the trading week clocking double- to triple-digit gains amid a flurry of corporate and macroeconomic developments that bolstered investing appetite. In the macroeconomic front alone, sentiment was boosted by the Federal Reserve’s decision to slash the benchmark rates by 25 basis points in its last committee meeting for the year.
In this article, we identified the names of the week’s heavy gainers and detailed the reasons behind their jump.
To come up with the list, we focused on the stocks with a $2 billion market capitalization and 5 million shares in trading volume. The stocks were chosen based on the percentage change in their share prices on December 5 and 12, 2025.
10. Americold Realty Trust Inc. (NYSE:COLD)
Americold grew its share prices by 18.4 percent week-on-week, as investors appeared to have loaded portfolios ahead of the Christmas season, when demand for its temperature-controlled services typically spikes amid higher inventories.
At intra-week trading, Americold Realty Trust Inc. (NYSE:COLD) jumped by as high as $12.83 before trimming gains to end Friday’s session at $12.73 apiece.
The rally can also be attributed to broader market optimism following the Federal Reserve’s decision to slash the benchmark rate by 25 basis points, which is expected to indirectly impact Americold Realty Trust Inc. (NYSE:COLD) through an increase in consumer spending.
In other news, the company reaffirmed its outlook for full-year 2025. For the warehouse segment alone, revenues from rent and storage, as well as services, are targeted to grow by 1 to 2 percent.
Same-store revenues are projected to either drop by as much as 4 percent or end flat year-on-year, while net operating income (NOI) is targeted to end 50 to 100 basis points lower than associated revenues.
Non-same-store NOI, on the other hand, is pegged at a range of $7 million to $13 million, while transportation and management NOI is expected at $40 million to $44 million.
In the third quarter of the year, Americold Realty Trust Inc. (NYSE:COLD) widened its attributable net loss by 207 percent to $11.37 million from $3.7 million in the same period last year.
Total revenues dipped by 1.5 percent to $663.7 million from $674.17 million year-on-year, primarily due to lower volumes in the warehouse segment and a decrease in transportation revenue.
9. Applied Optoelectronics Inc. (NASDAQ:AAOI)
Applied Optoelectronics jumped by 20.56 percent week-on-week despite slashing double-digit gains on Friday, after bagging a major order from a hyperscaler for its 800G data center transreceivers.
On Wednesday, Applied Optoelectronics Inc. (NASDAQ:AAOI) said that it secured a major order from a hyperscaler, which it refused to identify, but which analysts believed to be Amazon.
However, profit-taking persisted on Friday, dragging its share price down by 11.73 percent to close at $32.06 apiece. Still, the company recorded a 39 percent jump in intra-week trading.
“We are pleased to receive our first volume order for our 800G products from this major hyperscale customer,” said Applied Optoelectronics, Inc. (NASDAQ:AAOI) Chairman and CEO Thompson Li.
“Our customers need optical solutions that can scale to support the speed and performance required for today’s AI-powered data transmissions, and we believe that AOI is uniquely positioned to meet the demands for high-volume transceiver shipments with our automated production lines that we have spent years developing,” he added.
In line with the announcement, investment firm Needham & Company raised its price target for Applied Optoelectronics Inc. (NASDAQ:AAOI) to $43 from $38 previously, while maintaining its “buy” recommendation for the stock. The new figure marked a 34 percent upside potential from its latest closing price.
Additionally, Needham said it was optimistic that the company would further receive large volume orders from hyperscalers over the next few quarters as it ramps up the production of its 800G transreceivers.
8. Clear Secure, Inc. (NYSE:YOU)
Clear Secure surged by 22.6 percent week-on-week to hit a new four-year high, as investors took heart from JPMorgan turning bullish on its stock, having raised its rating and price target by 20 percent.
In Friday’s session alone, Clear Secure, Inc. (NYSE:YOU) jumped to its highest price of $42.07 before paring gains to end the day just up by 13.29 percent at $41.08 apiece.
In a market report, JPMorgan raised its rating for the stock to “overweight” from “neutral,” as well as its price target to $42 from $35 previously, on optimism that the latter would be able to renew its expiring contract with American Express at more favorable rates.
According to the investment firm, a more favorable contract would significantly bolster bookings for Clear Secure, Inc. (NYSE:YOU) in the second half of 2026.
In other news, the company bagged a contract with the Centers for Medicare & Medicaid Services (CMS) to support the modernization of identity verification for Medicare beneficiaries and providers.
Under the agreement, Clear Secure, Inc. (NYSE:YOU) would integrate its secure identity platform, CLEAR1, into CMS for account creation and recovery, as well as access to healthcare information. The contract is slated to start in early 2026.
7. Rocket Lab Corp. (NASDAQ:RKLB)
Rocket Lab jumped by 25.3 percent week-on-week, as investors loaded portfolios amid a series of rocket launches for the week, as well as the unveiling of its Neutron rocket called “Hungry Hippo.”
According to the company, it is scheduled to launch the “RAISE and Shine” Electron rocket at 4PM on Sunday, December 14 (NZDT) in support of its customer, Japan Aerospace Exploration Agency (JAXA).
The RAISE and Shine mission is the first of two launches for JAXA, which is intended to deploy the latter’s rapid innovative payload demonstration satellite-4 (RAISE-4) spacecraft, a single satellite that will demonstrate eight technologies developed by private companies, universities, and research institutions throughout Japan. The second launch for JAXA is scheduled to take place in the first quarter of 2026.
RAISE and Shine was originally slated to take off late in the week, but was rescheduled following strong ground winds at Rocket Lab Corp.’s (NASDAQ:RKLB) Launch Complex 1 in New Zealand.
Meanwhile, Rocket Lab Corp. (NASDAQ:RKLB) announced on Monday that it has completed the testing of its first Neutron rocket, Hungry Hippo, and has already sent it to its Launch Complex 3 at the Mid-Atlantic Regional Spaceport in Virginia.
Rocket Lab Corp. (NASDAQ:RKLB) began the development of Neutron in late 2021, with its first launch scheduled in 2026.
6. Confluent, Inc. (NASDAQ:CFLT)
Confluent soared by 29.9 percent week-on-week, as investors loaded portfolios following news that it was set to be acquired by IBM for $11 billion.
On Monday, Confluent, Inc. (NASDAQ:CFLT) said that it officially inked a definitive agreement with IBM, under which the latter would acquire all of the former’s outstanding common shares at a price of $31 apiece.
The transaction has already secured the approval of both firms’ board of directors, as well as Confluent, Inc.’s (NASDAQ:CFLT) largest shareholders who hold a combined 62 percent of its stake.
The transaction is expected to be completed in the middle of 2026, subject to customary closing conditions, including approval of minority shareholders and other regulatory approvals.
“IBM and Confluent together will enable enterprises to deploy generative and agentic AI better and faster by providing trusted communication and data flow between environments, applications, and APIs. Data is spread across public and private clouds, datacenter,s and countless technology providers,” IBM Chairman, President, and CEO Arvind Krishna.
“With the acquisition of Confluent, IBM will provide the smart data platform for enterprise IT, purpose-built for AI,” he noted.
5. EchoStar Corporation (NASDAQ:SATS)
EchoStar climbed by 30.94 percent week-on-week after rallying for seven consecutive days, as investors took heart from SpaceX’s billion-dollar public offering plan as well as an investment firm’s bullish coverage for its stock.
On Thursday alone, EchoStar Corporation (NASDAQ:SATS) jumped to an all-time high of $109.53 after Bloomberg reported that Elon Musk-led SpaceX—which it is a shareholder of—would pursue an initial public offering next year in a bid to raise more than $30 billion in fresh funds.
Bloomberg said that SpaceX may list publicly in June, targeting a valuation of around $1.5 trillion. EchoStar Corporation (NASDAQ:SATS), which currently owns $11.1 billion worth of SpaceX stock, stands to benefit from the IPO as it could substantially unlock the value of its investment.
In other news, EchoStar Corporation (NASDAQ:SATS) earned a higher price target of $110 from Morgan Stanley, versus $82 previously, as well as a rating upgrade of “overweight” versus “equal weight” prior.
According to the investment firm, EchoStar Corporation (NASDAQ:SATS) stands to benefit from the increasing competition in US wireless carriers.
“Spectrum is an appreciating asset, and we expect both Verizon (VZ) and T-Mobile (TMUS) to be aggressive in pursuing the remaining paired AWS-3 holdings at EchoStar,” it said.
4. Planet Labs PBC (NYSE:PL)
Planet Labs surged by 42.8 percent week-on-week to hit a new all-time high as investors loaded portfolios after posting an upbeat outlook for its business and earning a higher price target from an investment firm.
In an updated report earlier in the week, Planet Labs PBC (NYSE:PL) said that it was looking at revenues between $297 million and $301 million for the full fiscal year of 2025, higher than its earlier forecast of $281 million to $289 million.
The guidance followed strong results in the third quarter of the year, during which revenues jumped by 32.4 percent to $81.2 million from $61.3 million in the same period last year, beating its earlier guidance of $71 million to $74 million.
“We delivered a strong third quarter, marked by continued momentum in the business, accelerated revenue growth, and excellent progress on our profitability goals,” said Planet Labs PBC (NYSE:PL) Chairman and CEO Will Marshall.
However, net loss nearly tripled to $59 million from $20 million in the same comparable period.
Also for the full fiscal year, Planet Labs PBC (NYSE:PL) expects to swing to a positive adjusted EBITDA of $6 million to $8 million from an earlier guidance of adjusted EBITDA loss of up to $7 million.
In other developments, the company received a price target upgrade of $20 from Morgan Stanley, marking a 344 percent jump from its previous price target of $4.50. It also maintained an “equal weight” rating for the stock.
3. Warby Parker Inc. (NYSE:WRBY)
Warby Parker grew its share prices by 46 percent week-on-week to touch a new 52-week high as investors positioned their portfolios ahead of the looming launch of artificial intelligence glasses.
In a filing with the Securities and Exchange Commission (SEC) earlier in the week, Warby Parker Inc. (NYSE:WRBY) confirmed that the intelligent glasses, a new product line in partnership with Google, are set to be unveiled in 2026.
The AI glasses will incorporate multimodal AI with prescription and non-prescription lenses.
Warby Parker Inc. (NYSE:WRBY) and Google entered into a partnership agreement in May, under which the former would design and develop the AI glasses, while the latter would shell out $75 million for product development, alongside an optional $75 million investment in the eyewear-maker, subject to the achievement of certain milestones.
“Since our launch, we’ve set out to transform the optical industry by leveraging pioneering technology to design better products and experiences—and over the past 15 years, we’ve done just that,” said Warby Parker Inc. (NYSE:WRBY) co-Founder and co-CEO Dave Gilboa.
“Looking ahead, we believe multimodal AI is perfectly suited for glasses, enabling real-time context and intelligence to augment a wearer’s surroundings as they move through the world. We couldn’t be more excited to be partnering with Google to bring together the best of AI and the best of eyewear,” he added.
2. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML).
In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in the conditions of 63 enrolled patients after taking the pill for 24 weeks.
Additionally, it saw a 74 percent major molecular response rate at higher doses of 320 mg.
Of the total enrollees, 55 patients remained on treatment, with four dropping out due to disease progression.
Meanwhile, three stopped due to the physician and patient’s decision, while one stopped after experiencing adverse effects.
Following the results, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) received a 107 percent higher price target of $58 from investment firm Oppenheimer, alongside an “outperform” rating for its stock.
According to Oppenheimer, the encouraging results support TERN-701’s potential as a “best-in-class” therapy in the CML market.
In other news, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) successfully raised $747.5 million in fresh funds from the issuance of more than 18.68 million shares to the public.
The total included the underwriters’ full exercise of their overallotment option covering 2.4 million shares at the offer price of $40 apiece.
The company said part of the proceeds will be allocated for the development, manufacturing, preparation, and future commercial launch of TERN-701, while the balance will be used for working capital and other general corporate purposes.
1. Wave Life Sciences Ltd. (NASDAQ:WVE)
Wave Life Sciences nearly tripled its share price on a week-on-week basis, as investors positioned their portfolios after the encouraging results of its obesity drug clinical trial, sparking rosy prospects for the company in a highly coveted industry.
At intra-week trading, Wave Life Sciences Ltd. (NASDAQ:WVE) soared by as much as 190 percent to touch a new six-year high of $21.73 before trimming gains to finish the week just up by 121 percent.
This followed stellar results from the first phase of its clinical trial to test the efficacy of WVE-007 on obese patients, where enrollees’ body composition significantly improved.
According to Wave Life Sciences Ltd. (NASDAQ:WVE), WVE-007, taken in just three months, resulted in a 4.5 percent total fat loss, 9.4 percent visceral fat reduction, and a 3.2 percent increase in lean mass.
Notably, investors cheered the drug candidate’s safety and tolerability results, having no recorded serious adverse reactions during the course of the trial.
Wave Life Sciences Ltd (NASDAQ:WVE) said it expects to deliver the results of the second round of the clinical trial, covering six months for the 240 mg single-dose cohort, as well as three-month follow-up data for the 400mg single-dose cohort.
It also targets to deliver the six-month data for the 400mg single-dose cohort and the three-month follow-up data from the 600mg single-dose cohort in the second quarter of 2026.
For phase 2, Wave Life Sciences Ltd (NASDAQ:WVE) would target to evaluate WVE-007 as both a monotherapy and an add-on therapy to incretins in populations with higher BMI and related co-morbidities, and as a maintenance therapy post-incretin treatment.
While we acknowledge the potential of WVE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WVE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
